Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients.
Widenmeyer M, Griesemann H, Stevanović S, Feyerabend S, Klein R, Attig S, Hennenlotter J, Wernet D, Kuprash DV, Sazykin AY, Pascolo S, Stenzl A, Gouttefangeas C, Rammensee HG.
Widenmeyer M, et al. Among authors: stenzl a.
Int J Cancer. 2012 Jul 1;131(1):140-9. doi: 10.1002/ijc.26365. Epub 2011 Sep 14.
Int J Cancer. 2012.
PMID: 21858810
Clinical Trial.